OBSOLETE: Limbic encephalitis with LGI1 antibodies Advocacy Hub | UniteRare

At a Glance

Live from database

💊

1FDA treatments

💰

1Open funds

Regulatory Watchboard

1 event

Jul 2022

Krystexxa: FDA approved

Treatment of chronic gout in adult patients refractory to conventional therapy

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Patient Assistance Programs1

Krystexxa

Horizon Therapeutics Ireland DAC

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Krystexxa

(pegloticase)Orphan drug

Horizon Therapeutics Ireland DAC

Uric Acid-specific Enzyme [EPC]

12.1 Mechanism of Action KRYSTEXXA is a uric acid specific enzyme which is a recombinant uricase and achieves its therapeutic effect by catalyzing the...

Approved Jul 2022FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for OBSOLETE: Limbic encephalitis with LGI1 antibodies.
Search all trials →

Search clinical trials for OBSOLETE: Limbic encephalitis with LGI1 antibodies →

Recent News & Research

No recent news articles indexed yet for OBSOLETE: Limbic encephalitis with LGI1 antibodies.
Search PubMed for OBSOLETE: Limbic encephalitis with LGI1 antibodies →

Browse all OBSOLETE: Limbic encephalitis with LGI1 antibodies news →

Specialist Network

No specialists currently listed for OBSOLETE: Limbic encephalitis with LGI1 antibodies.

View all OBSOLETE: Limbic encephalitis with LGI1 antibodies specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰